Want to see TSE:COV full AI Analyst Report?
Covalon Technologies (COV) AI Stock Analysis
Top Page
Covalon Technologies
(TSXV:COV)
The score is driven primarily by improving fundamentals (return to profitability, stronger cash flow, and very low leverage) and strong technical momentum (price above all major moving averages with positive MACD). These positives are tempered by a relatively elevated P/E and only moderate, slowing revenue growth, which increases the need for continued margin and execution progress.
Covalon Technologies (COV) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 122.35M
- Dividend Yield
- ―
- Average Volume (3M)
- 27.35K
- Price to Earnings (P/E)
- 28.2
- Beta (1Y)
- 0.20
- Revenue Growth
- 4.11%
- EPS Growth
- 88.39%
- Country
- Canada
- Employees
- 105
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Instruments & Supplies
Covalon Technologies Business Overview & Revenue Model
Company Description
Covalon Technologies Ltd., a Canadian company based in Mississauga, innovates, develops, manufactures, and commercializes medical technologies and products globally. Its operations span major international markets, including North America, Europe, th...
How the Company Makes Money
Covalon makes money primarily by selling its wound care and infection prevention products to healthcare providers and through channel partners that distribute medical supplies. Revenue is generated from product sales (i.e., the shipment of consumable...
Covalon Technologies Earnings Call Summary
The earnings call highlighted strong sequential revenue growth, successful international expansion, and a robust cash position, indicating positive forward momentum. However, year-over-year revenue decline and decreased adjusted EBITDA present concerns, although these may be offset by promising innovations and clinical study results.
Q3-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During Covalon's Q3 Fiscal 2025 conference call, CEO Brent Ashton provided optimistic guidance, emphasizing key financial and operational metrics. The company reported $8.4 million in revenue for Q3, marking a sequential increase of over 10% from Q2, driven by more than 40% growth in its U.S. advanced wound care sales. Despite a year-over-year revenue decline of 9% for Q3, the company achieved an adjusted EBITDA of nearly $1 million, reflecting a 50% increase from the previous quarter. Ashton highlighted a robust 13% growth in trailing 12-month revenue and a 27% compounded annual growth rate over three years, illustrating Covalon's market success. Additionally, the company maintained a strong cash position of over $18 million, up almost $9 million from the previous year. Operationally, Covalon achieved 100% retention of its top 50 U.S. hospital customers and added 15 new hospital accounts in Q3, with a total of 65 new accounts for the year. Ashton also shared promising updates on the company's innovation pipeline and international market expansion, including new product registrations and distribution agreements.
Covalon Technologies Financial Statement Overview
Summary
Financials show a clear recovery: TTM profitability is positive again, gross margin is solid (~53%), and cash generation improved with operating cash flow exceeding net income (~1.64x). Balance sheet risk is low with very low leverage (~0.06 debt-to-equity) and a strong equity base. The main constraint is that operating/EBITDA margins are still modest and revenue growth has slowed (~5% TTM), making results more sensitive to cost pressure.
Income Statement
72PositiveBalance Sheet
86Very PositiveCash Flow
82Very Positive| Breakdown | TTM | Sep 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.35M | 32.82M | 31.17M | 26.60M | 18.15M | 19.56M |
| Gross Profit | 19.95M | 17.47M | 18.93M | 14.36M | 7.49M | 9.70M |
| EBITDA | 4.94M | 3.01M | 3.14M | -3.56M | -8.11M | 1.54M |
| Net Income | 4.39M | 2.06M | 2.67M | -4.46M | -9.66M | 23.48M |
Balance Sheet | ||||||
| Total Assets | 36.57M | 36.12M | 31.81M | 24.90M | 30.38M | 40.58M |
| Cash, Cash Equivalents and Short-Term Investments | 19.39M | 17.37M | 16.75M | 8.79M | 14.06M | 22.95M |
| Total Debt | 1.69M | 2.25M | 901.67K | 1.56M | 2.17M | 2.59M |
| Total Liabilities | 5.03M | 5.40M | 4.30M | 6.11M | 6.15M | 7.21M |
| Stockholders Equity | 31.55M | 30.73M | 27.50M | 18.79M | 24.23M | 33.37M |
Cash Flow | ||||||
| Free Cash Flow | 5.51M | 1.65M | 3.06M | -4.50M | -9.08M | 443.71K |
| Operating Cash Flow | 6.78M | 2.29M | 3.47M | -3.18M | -7.99M | 621.37K |
| Investing Cash Flow | -1.43M | -847.02K | -281.63K | -81.02K | -843.02K | -278.53K |
| Financing Cash Flow | -4.83M | -529.35K | 4.97M | -2.16M | -2.19M | -8.25M |
Covalon Technologies Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:COV, the sentiment is Positive. The current price of 4.43 is above the 20-day moving average (MA) of 4.14, above the 50-day MA of 3.67, and above the 200-day MA of 2.39, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 60.33 is Neutral, neither overbought nor oversold. The STOCH value of 94.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:COV.
Covalon Technologies Peers Comparison
Overall Rating
- TSE:COV79Outperform
TSE:NRX49Neutral
TSE:MIR47Neutral
TSE:DTC43Neutral
TSE:SVA41Neutral
TSE:MDNA40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:COV | 79Outperform | CAD 122.35M | 28.16 | 15.04% | ― | 4.11% | 88.39% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TSE:NRX | 49Neutral | CAD 37.32M | -4.51 | -337.24% | ― | ― | 19.02% |
| TSE:MIR | 47Neutral | CAD 37.19M | -11.36 | 12.68% | ― | 45.72% | 35.82% |
| TSE:DTC | 43Neutral | CAD 26.53M | -3.17 | -424.91% | ― | ― | -54.70% |
| TSE:SVA | 41Neutral | CAD 39.65M | -3.57 | 57.10% | ― | ― | 48.06% |
| TSE:MDNA | 40Underperform | CAD 35.32M | -2.06 | -360.29% | ― | ― | -33.27% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:COV | Covalon Technologies | 4.43 | 2.33 | 110.95% | |
| TSE:MDNA | Medicenna Therapeutics | 0.46 | -1.04 | -69.67% | |
| TSE:MIR | Medmira Inc | 0.05 | -0.02 | -29.33% | |
| TSE:SVA | Sernova Corp | 0.10 | -0.04 | -30.00% | |
| TSE:NRX | Nurexone Biologic Inc. | 0.48 | -0.21 | -30.43% | |
| TSE:DTC | Defence Therapeutics Inc | 0.35 | -0.45 | -56.25% |
Covalon Technologies Corporate Events
Covalon to Spotlight IV Pathway Protection Portfolio at 2026 ANCC Magnet Conference
PositiveCovalon Technologies will showcase its contamination protection and infection-prevention portfolio at the 2026 ANCC National Magnet & Pathway to Excellence Conference in Chicago, an event that draws more than 10,000 nursing professionals and heal...
Covalon’s Collagen Dressing Shows Strong Real-World Performance in Hard-to-Heal Wounds
PositiveCovalon Technologies reported positive results from a retrospective real-world evidence analysis comparing its collagen matrix wound dressing to five competing collagen products in U.S. outpatient wound centers. Using de-identified records from the U...
Covalon to Spotlight Record Quarter at Smallcap Discoveries Conference
PositiveCovalon Technologies will present at the 2026 Annual Smallcap Discoveries Conference in Vancouver following its strongest fiscal quarter in recent history. The company reported third-quarter revenue above $10 million, up 20% year over year, a sharply...
Covalon’s Contamination Protection Drives Record Q3 Revenue and Margins
PositiveCovalon Technologies reported a strong fiscal 2026 third quarter, highlighting revenue growth and margin expansion driven by its advanced medical technologies portfolio. The company’s contamination protection solutions for vascular access sites...
Covalon Sets August 27 Call to Discuss Q3 2026 Results
PositiveCovalon Technologies will release its third-quarter fiscal 2026 results on August 27, 2026, before markets open, and will host a conference call and webcast at 8:30 a.m. ET the same day to review the performance. The call will include a Q&A sessi...
Covalon Sets Investor Call for Q3 Fiscal 2026 Results
PositiveCovalon Technologies will release its third quarter fiscal 2026 results on August 27, 2026, before markets open, and has scheduled a conference call and webcast that morning at 8:30 a.m. ET for investors and analysts. The company will make a recordin...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 06, 2026